EA201491643A1 - Идентификация мутаций канал-опсина-2 (chop2) и способы применения - Google Patents

Идентификация мутаций канал-опсина-2 (chop2) и способы применения

Info

Publication number
EA201491643A1
EA201491643A1 EA201491643A EA201491643A EA201491643A1 EA 201491643 A1 EA201491643 A1 EA 201491643A1 EA 201491643 A EA201491643 A EA 201491643A EA 201491643 A EA201491643 A EA 201491643A EA 201491643 A1 EA201491643 A1 EA 201491643A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chop2
opsin
canal
mutations
identification
Prior art date
Application number
EA201491643A
Other languages
English (en)
Inventor
Чжо-хуа Пань
Original Assignee
Уэйн Стейт Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уэйн Стейт Юниверсити filed Critical Уэйн Стейт Юниверсити
Publication of EA201491643A1 publication Critical patent/EA201491643A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В изобретении предлагаются композиции и наборы реагентов, включающие по меньшей мере одну молекулу нуклеиновой кислоты или полипептидную молекулу, кодирующую мутантный белок ChR2. Способы по изобретению включат введение объекту композиции, включающей мутантный ChR2, для сохранения, улучшения или восстановления фотопреобразования. Предпочтительно, композиции и способы по изобретению предлагаются объекту с нарушенным зрением, восстанавливая таким образом зрение до нормального уровня.
EA201491643A 2012-03-05 2013-03-05 Идентификация мутаций канал-опсина-2 (chop2) и способы применения EA201491643A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Publications (1)

Publication Number Publication Date
EA201491643A1 true EA201491643A1 (ru) 2015-02-27

Family

ID=47892055

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491643A EA201491643A1 (ru) 2012-03-05 2013-03-05 Идентификация мутаций канал-опсина-2 (chop2) и способы применения

Country Status (17)

Country Link
US (2) US10947281B2 (ru)
EP (1) EP2822964B1 (ru)
JP (3) JP6395611B2 (ru)
KR (1) KR102137717B1 (ru)
CN (2) CN111378020A (ru)
AU (4) AU2013230112A1 (ru)
CA (1) CA2866405A1 (ru)
DK (1) DK2822964T3 (ru)
EA (1) EA201491643A1 (ru)
ES (1) ES2703324T3 (ru)
HK (1) HK1205744A1 (ru)
HU (1) HUE040487T2 (ru)
MX (1) MX360085B (ru)
NZ (1) NZ629843A (ru)
PL (1) PL2822964T3 (ru)
PT (1) PT2822964T (ru)
WO (1) WO2013134295A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470790B2 (en) 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
HUE040487T2 (hu) * 2012-03-05 2019-03-28 Univ Wayne State Csatornarodopszin-2 (CHOP2) mutációk azonosítása és alkalmazási eljárások
EP2968476B1 (en) 2013-03-14 2021-05-05 Wayne State University A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
EP3019473B1 (en) 2013-07-08 2020-02-19 Basf Se Oxime ester photoinitiators
WO2015138616A1 (en) 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use
SG11201809532QA (en) 2016-05-03 2018-11-29 Univ Wayne State Method of enhancing viral-mediated gene delivery in the eye using proteosome inhibitors
US20190218256A1 (en) * 2016-06-03 2019-07-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mutant light-inducible ion channel of channelrhodopsin
SG10202102061SA (en) * 2016-08-29 2021-04-29 Univ Wayne State Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
EP3535282A4 (en) * 2016-11-06 2020-04-08 Nanoscope Technologies LLC OPTOGENETIC MODULATION BY OPSINE WITH SEVERAL PROPERTIES FOR THE RESTORATION OF SIGHT AND OTHER APPLICATIONS THEREOF
US20200115419A1 (en) * 2017-04-12 2020-04-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
PT3720428T (pt) * 2017-12-04 2023-04-03 Salvat Lab Sa Composição tópica oftálmica compreendendo ácido dobesílico para tratamento de doenças do segmento posterior do olho
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
WO1998048027A2 (en) 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
AU775245B2 (en) 1998-09-17 2004-07-22 Catholic University Nijmegen Methods for treatment of degenerative retinal diseases
AU2001255575B2 (en) 2000-04-28 2006-08-31 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
EP1381276A4 (en) 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
US7144733B2 (en) 2001-08-16 2006-12-05 Sloan-Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
WO2004009022A2 (en) 2002-07-18 2004-01-29 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7427138B2 (en) 2003-11-05 2008-09-23 Neurovision, Inc. Method and apparatus for improving visual perception
US9278159B2 (en) 2005-07-22 2016-03-08 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US8470790B2 (en) 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
WO2011140279A1 (en) * 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
RU2595384C2 (ru) * 2010-09-08 2016-08-27 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Мутантный канальный родопсин-2
HUE040487T2 (hu) 2012-03-05 2019-03-28 Univ Wayne State Csatornarodopszin-2 (CHOP2) mutációk azonosítása és alkalmazási eljárások
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
DK2822964T3 (en) 2018-12-10
AU2017239601B2 (en) 2019-05-16
JP2015510759A (ja) 2015-04-13
AU2013230112A1 (en) 2014-09-25
AU2019216638A1 (en) 2019-09-05
HUE040487T2 (hu) 2019-03-28
EP2822964B1 (en) 2018-08-22
HK1205744A1 (en) 2015-12-24
US20220033449A1 (en) 2022-02-03
JP2019193656A (ja) 2019-11-07
PT2822964T (pt) 2018-11-29
MX360085B (es) 2018-10-10
US20150044181A1 (en) 2015-02-12
AU2019216638B2 (en) 2021-07-08
AU2021245195B2 (en) 2023-09-28
NZ727041A (en) 2022-01-28
ES2703324T3 (es) 2019-03-08
NZ629843A (en) 2017-03-31
AU2017239601A1 (en) 2017-10-26
KR102137717B1 (ko) 2020-07-27
WO2013134295A1 (en) 2013-09-12
AU2021245195A1 (en) 2021-11-04
PL2822964T3 (pl) 2019-05-31
CN104334575A (zh) 2015-02-04
CN111378020A (zh) 2020-07-07
KR20140132401A (ko) 2014-11-17
JP6395611B2 (ja) 2018-09-26
JP2018134098A (ja) 2018-08-30
CA2866405A1 (en) 2013-09-12
US10947281B2 (en) 2021-03-16
MX2014010664A (es) 2015-03-06
EP2822964A1 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
MX2021010668A (es) Proteinas de fusion de citoquinas.
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
BR112018074700A2 (pt) variantes de protease e usos das mesmas
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
EA201491644A1 (ru) Фармацевтические композиции
EA201691111A1 (ru) Химерные белки фактора viii и их применение
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EA201590845A1 (ru) Варианты fc-гамма-рецептора iib
TR201910117T4 (tr) OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları.
MX2019002321A (es) Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas.
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
EA201792608A3 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение